President Donald Trump announced a plan on Sunday to cut prescription drug prices in the U.S., triggering sharp market fluctuations across Asian markets. His executive order, slated for release Monday, aims to slash costs by 30-80% and implement a “most favoured nation” rule, which would ensure America never pays more than other nations for the same medicines. The proposal comes with an aggressive stance against pharmaceutical companies, who have historically resisted price cap initiatives due to concerns about research funding. Trump asserts that this new order will finally level the playing field. Industry experts remain divided on the plan’s legal feasibility and impact on drug development, but stock prices in Asian pharma giants like Chugai Pharmaceutical Co., Daiichi Sankyo Co., Takeda Pharmaceutical Co., and South Korean companies such as SK Biopharmaceuticals, Celltrion Inc., and Samsung Biologics have been impacted. Concerns linger about potential retaliatory measures by other countries and how this policy might affect the profitability of drug makers who rely on U.S. sales for research and development in cancer treatments and cutting-edge therapies. The White House has not released a full text of the order, but observers anticipate legal challenges to its implementation.